EFM
E Fund Management Portfolio holdings
AUM
$2.1B
1-Year Return
23.31%
This Quarter Return
-7.88%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
-$29.7M
(-2.7%)
Cap. Flow
+$88.7M
Cap. Flow
% of AUM
8.26%
Top 10 Holdings %
Top 10 Hldgs %
55.73%
Holding
349
New
26
Increased
163
Reduced
134
Closed
15
Top Buys
| 1 |
TSMC
TSM
|
$29.5M |
| 2 |
Grab
GRAB
|
$28.9M |
| 3 |
Qualcomm
QCOM
|
$21.2M |
| 4 |
Advanced Micro Devices
AMD
|
$16.3M |
| 5 |
Sea Limited
SE
|
$14.7M |
Top Sells
| 1 |
Mercado Libre
MELI
|
$25.6M |
| 2 |
Meta Platforms (Facebook)
META
|
$13.4M |
| 3 |
DIDI
DiDi Global Inc. American depositary shares, each four representing one Class A ordinary share
DIDI
|
$6.5M |
| 4 |
IMAB
I-MAB
IMAB
|
$1.24M |
| 5 |
ProShares Ultra Gold
UGL
|
$1.01M |
Sector Composition
| 1 | Consumer Discretionary | 34.29% |
| 2 | Technology | 26.19% |
| 3 | Communication Services | 11.91% |
| 4 | Healthcare | 11.24% |
| 5 | Real Estate | 7.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
Idexx Laboratories
IDXX
$51.4B
| $444K | 0.04% |
1,364
+105
| +8% | +$34.2K |
|
152
Prothena Corp
PRTA
$460M
| $444K | 0.04% |
7,329
-2,016
| -22% | -$122K |
|
|
SAGE
153
DELISTED
Sage Therapeutics
SAGE
| $444K | 0.04% |
11,341
+446
| +4% | +$17.5K |
|
154
Alkermes
ALKS
$4.94B
| $443K | 0.04% |
19,839
+3,893
| +24% | +$86.9K |
|
155
Coca-Cola
KO
$292B
| $442K | 0.04% |
7,882
+135
| +2% | +$7.57K |
|
156
Rhythm Pharmaceuticals
RYTM
$6.78B
| $442K | 0.04% |
+18,035
| New | +$442K |
|
157
Exelon
EXC
$43.9B
| $441K | 0.04% |
11,772
+465
| +4% | +$17.4K |
|
158
Bristol-Myers Squibb
BMY
$96B
| $439K | 0.04% |
6,182
+637
| +11% | +$45.2K |
|
159
Denali Therapeutics
DNLI
$2.26B
| $437K | 0.04% |
14,254
+2,613
| +22% | +$80.1K |
|
|
CTIC
160
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $437K | 0.04% |
75,133
+24,962
| +50% | +$145K |
|
161
BioMarin Pharmaceuticals
BMRN
$11.1B
| $435K | 0.04% |
5,126
-706
| -12% | -$59.9K |
|
162
Amicus Therapeutics
FOLD
$2.46B
| $435K | 0.04% |
41,712
-10,727
| -20% | -$112K |
|
|
KRTX
163
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $431K | 0.04% |
1,914
-2,402
| -56% | -$541K |
|
164
Alnylam Pharmaceuticals
ALNY
$59.2B
| $427K | 0.04% |
2,134
-1,181
| -36% | -$236K |
|
165
Dynavax Technologies
DVAX
$1.18B
| $427K | 0.04% |
40,888
+10,569
| +35% | +$110K |
|
166
Bank of America
BAC
$369B
| $424K | 0.04% |
14,027
-51
| -0.4% | -$1.54K |
|
167
Cytokinetics
CYTK
$6.34B
| $423K | 0.04% |
8,738
-2,348
| -21% | -$114K |
|
|
BLUE
168
DELISTED
bluebird bio
BLUE
| $422K | 0.04% |
+3,336
| New | +$422K |
|
|
VERV
169
DELISTED
Verve Therapeutics
VERV
| $422K | 0.04% |
+12,292
| New | +$422K |
|
170
Xcel Energy
XEL
$43B
| $419K | 0.04% |
6,541
+258
| +4% | +$16.5K |
|
|
171
Mercado Libre
MELI
$123B
| $418K | 0.04% |
505
-30,976
| -98% | -$25.6M |
|
172
Exelixis
EXEL
$10.2B
| $417K | 0.04% |
26,611
+2,473
| +10% | +$38.8K |
|
173
Intellia Therapeutics
NTLA
$1.29B
| $414K | 0.04% |
7,393
-2,922
| -28% | -$164K |
|
|
BPMC
174
DELISTED
Blueprint Medicines
BPMC
| $413K | 0.04% |
6,262
-2,847
| -31% | -$188K |
|
175
Insmed
INSM
$30.7B
| $413K | 0.04% |
19,185
-1,821
| -9% | -$39.2K |
|